BASF: In-House Development and Fermentation in Focus
The German chemical company BASF is strictly aligning its agricultural division with the 2030 sustainability goals and aims to expand its market share for environmentally friendly products in a targeted manner. Rather than relying primarily on acquiring plant-based solutions, as other industry giants do, BASF focuses on discovering biological microbial strains and relies on its own fermentation facilities for industrial production. Furthermore, the company is actively forming alliances in the hardware sector. Together with its partner AMVAC, BASF is integrating the Rhizo-Flo granule into the SIMPAS precision application system. BASF is focusing on specific areas within the biologics sector but aims to grow even further in this promising niche.
Corteva: Course Set After Active Ingredient Phase-Out
Following its regulatory-mandated phase-out of the insecticide chlorpyrifos, the US-based company Corteva is aiming for a leading role in the market for sustainable agricultural solutions. To this end, management established a dedicated division and strengthened it through the acquisition of specialists such as Symborg. Through this acquisition, Corteva secured global rights to the microorganism Methylobacterium symbioticum, which colonizes leaves and fixes nitrogen directly from the air, thereby reducing the need for fertilizer. In addition, Corteva is expanding its portfolio through collaborations and licensing agreements with competitors. Corteva’s focus is thus primarily on microbiomes and acquisitions.
MustGrow Biologics: Revolutionizing Organic Crop Protection Thanks to Mustard Seeds
The Canadian agtech company MustGrow Biologics relies on the extraction of natural active ingredients from mustard seeds, and its products deliver remarkable results. Using enzymatic processes, MustGrow extracts biologically active compound from mustard that form in situ allyl isothiocyanate, which is the spice we taste when we eat mustard products. With its proprietary liquid formulation TerraMG™, MustGrow Biologics has succeeded in keeping the volatile active ingredient stable until application, after which the product rapidly degrades in the soil within 48-72 hours. Numerous field trials demonstrate that the biopesticide significantly reduces infestation in most cases and is highly efficacious compared to synthetic agents such as chloropicrin. Applications of TerraMG™ range from soil treatment against fungi such as Fusarium or Verticillium to post-harvest treatment of potatoes. In addition, the company markets TerraSante™, a biological soil fertility product designed to enhance soil microbiome activity.
Global Licenses and Targeted Collaborations for Greater Scale
To unlock the technology’s full potential, MustGrow Biologics is focusing on global licensing and collaboration with partners. A key foundation is an exclusive commercialization and licensing agreement with Bayer, which has been in place since 2023 for the regions of Europe, the Middle East, and Africa. Bayer is covering all costs for regulatory submissions, field development, and trials. MustGrow Biologics’ management estimates the total value of upfront and milestone payments, as well as market-related development contributions from Bayer, at USD 35 million to USD 40 million over a period of 5 to 7 years, excluding future revenue shares. Demand for MustGrow’s solutions appears to be high. The company closed its distribution subsidiary in April 2026 and announced that it would focus on increasing production of TerraSante™ through external partnerships.
Conclusion: MustGrow Biologics Earns Analysts’ Confidence
MustGrow Biologics may be an attractive opportunity based on its current fundamentals. In a commissioned study, analysts at GBC AG forecast a sharp increase in revenue from CAD 4.5 million in 2026 to more than CAD 31.5 million by 2028. The analysts have assigned a price target of CAD 2.70 and maintain a “Buy” recommendation. Key catalysts for future growth include the continued expansion of the company’s North American commercial operations and upcoming milestones in its licensing partnership with Bayer. Key risks include potential commercialization delays and fluctuations in the prices of raw materials, such as mustard seed. After a significant share price decline in recent months, MustGrow’s market capitalization has fallen to approximately CAD 22 million. For investors with a higher risk tolerance, the stock could represent an opportunity to gain exposure to the growing market for innovative agricultural solutions.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
